(Q34727773)

English

Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function (English)

1 reference

Europe PubMed Central

4 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Michael Mayer

1

1 reference

Europe PubMed Central

4 August 2017

Sai Nudurupati

2

1 reference

Europe PubMed Central

4 August 2017

Xuejun Peng

3

1 reference

Europe PubMed Central

4 August 2017

John Marcinak

4

1 reference

Europe PubMed Central

4 August 2017

publication date

1 December 2014

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

14

1 reference

Europe PubMed Central

4 August 2017

4

1 reference

Europe PubMed Central

4 August 2017

273-282

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

6 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

Achieving glycemic control in patients with type 2 diabetes and renal impairment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269813

7 July 2018

The unrecognized prevalence of chronic kidney disease in diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40268-014-0066-4

21 January 2018

The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.

1 reference

https://api.crossref.org/works/10.1007%2FS40268-014-0066-4

21 January 2018

A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40268-014-0066-4

21 January 2018

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25374042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25374042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25374042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of chronic renal failure on drug metabolism and transport

1 reference

https://pubmed.ncbi.nlm.nih.gov/25374042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40268-014-0066-4

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34727773&oldid=2144530969"